Erythropoietin and VEGF exhibit equal angiogenic potential
Erythropoietin and VEGF exhibit equal angiogenic potential
复制标题
DOI：
10.1006/mvre.2002.2426
复制
发表时间：
2002-09-01
影响因子：
3.1
通讯作者：
Kuck, KH
中科院分区：
文献类型：
--
作者：
Jaquet, K;Krause, K;Kuck, KH
促红细胞生成素（Epo）是一种调节红系细胞增殖和分化的激素。造血细胞和内皮细胞共享共同的成血管细胞祖细胞的假设是基于两种细胞谱系表达细胞表面抗原如CD31和CD34的发现。在这项研究中，我们研究了重组人促红细胞生成素（rHuEpo）对成人心肌组织来源的内皮细胞的血管生成潜力。此外，我们比较了rHuEpo与其他细胞因子（VEGF，aFGF）和生长因子组合的血管生成潜力。在冠状动脉搭桥手术期间获得心肌组织（心脏耳廓）样品，包埋在纤维蛋白凝胶基质中，并培养21天。在倒置相差显微镜下用目镜分划板测量毛细血管发芽。用免疫组化和RT-PCR方法对成管内皮细胞进行鉴定。使用浓度为2.5 U/ml，我们发现，rHuEpo刺激毛细血管生长高达220%，相比nonstimulated生理生长。因此，在我们的体外试验中，Epo在内皮细胞上表现出与VEGF相同的血管生成潜力（165）（增加230%）。促红细胞生成素在成人心肌组织体外血管生成试验中刺激毛细血管生长。这意味着促红细胞生成素在血管增生过程中的作用。rHuEpo可作为缺血性心脏病患者的直接血管生成物质。(C)2002 Elsevier Science（美国）。
Erythropoietin (Epo) is a hormone regulating proliferation and differentiation of erythroid cells. The hypothesis that hematopoietic and endothelial cells share a common hemangioblast progenitor among others is based on the finding that both cell lineages express cell surface antigens like CD31 and CD34. In this study we investigated the angiogenic potential of recombinant human erythropoietin (rHuEpo) on endothelial cells derived from human adult myocardial tissue. In addition, we compared the angiogenic potential of rHuEpo to that of other cytokines (VEGF, aFGF) and combinations of growth factors. Samples of myocardial tissue (cardiac auricle) were obtained during coronary bypass surgery, embedded in a fibrin gel matrix, and cultured for 21 days. Capillary sprouting was measured with an eye-piece graticule under an inverted-phase contrast microscope. Tube-forming endothelial cells were characterized by immunohistochemistry and RT-PCR. Using a concentration of 2.5 U/ml, we found that rHuEpo stimulates capillary outgrowth up to 220%, compared to the nonstimulated physiological outgrowth. Epo therefore exhibits the same angiogenic potential on endothelial cells in our in vitro assay as VEGF(165) (230% increase). Erythropoietin stimulates capillary outgrowth in an in vitro angiogenesis assay using adult human myocardial tissue. This implies a role of erythropoietin in vasoproliferative processes. rHuEpo may serve as a direct angiogenic substance in patients with ischemic heart disease. (C) 2002 Elsevier Science (USA).